PMID: 42250575

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

Bajaj Harpreet S, Welch Michelle, Shah Parag, Luna Eduardo, Jaouimaa Fatima-Zahra, Liu Bing, Liu Rong, Chen Yanyun, Patel Hiren, Bartee Amy

Lancet (London, England) · 2026

Vol. 407, Issue 10546, pp. 2402-2413

This entry links to third-party literature. For research use only.